



14<sup>th</sup> July 2009

## **PRESS RELEASE**

### **LATEST UNIVERSITY OF SYDNEY PUBLICATION SUGGESTS L-DEX™ TECHNIQUE “MOST SUITED FOR THE EARLY DETECTION OF OR MONITORING OF THE EARLY STAGE OF LYMPHEDEMA”<sup>1</sup>.**

In their most recent publication released last month, scientists from the University of Sydney’s Breast Cancer Research Group have cross validated the use of ImpediMed’s L-Dex devices to a volumetric method of lymphoedema detection and monitoring (electro-optical perometry).

The publication highlights that perometry measures the limb volume which includes extracellular fluid, lean muscle mass and fat mass whereas L-Dex measures the extracellular fluid (including lymph) alone. For this reason the team from Sydney have stated that although perometry is a valid form of assessment, “The impedance technique would appear to be most suited for the early detection of or the monitoring of early stage lymphedema when changes are predominantly in the extracellular fluid volume”<sup>1</sup>.

With growing numbers of publications confirming the seriousness of the lymphoedema issue both in Australia and the rest of the world <sup>2,3,4,5,6</sup> an increase in the awareness of the benefits of early detection, intervention and monitoring is occurring <sup>7,8</sup>. This is in turn driving the use of tools like L-Dex to improve the earlier clinical assessment of the disorder and the implementation of pre-emptive care rather than today’s reactive care.

ImpediMed’s CEO Greg Brown said, “This publication is yet another confirmation of ImpediMed’s position as the provider of the technology of choice in aiding in the clinical assessment of early stage or subclinical lymphoedema, for which ImpediMed has the only FDA cleared devices.”

**ENDS**

#### **For further information contact:**

**Greg Brown**

**ImpediMed CEO**

**+61-7-3860-3700**

1. Ward, L.C., S. Czerniec, and S.L. Kilbreath, *Operational equivalence of bioimpedance indices and perometry for the assessment of unilateral arm lymphedema*. *Lymphat Res Biol*, 2009. 7(2): p. 81-5
2. <http://www.theaustralian.news.com.au/story/0,25197,25690834-23289,00.html>
3. European CanCer Organisation, Cancer survivors are living "in limbo" with unmet needs for care, 29 May 2008: <http://www.ecco-org.eu/News/News>
4. Hayes, S.C., et al., Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. *J Clin Oncol*, 2008. 26(21): p. 3536-42
5. Shih, Y.C., et al., *Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study*. *J Clin Oncol*, 2009.
6. NBOCC, *Review of research evidence on secondary lymphoedema: Incidence, prevention, risk factors and treatment*, S. Hayes, Editor. 2008, National Breast and Ovarian Cancer Centre. Review of research evidence on secondary lymphoedema: Incidence, prevention, risk factors and treatment, NBOCC, Surry Hills, NSW, 2008.
7. Gergich N, Washington F, Pfalzer L, Soballe P and McGarvey C , Preoperative assessment enables the early diagnosis and successful treatment of lymphedema., *Cancer*, Vol 112, pp 2809-2819, June 2008.
8. Hayes, S., et al., Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. *Lymphology*, 2008. 41(1): p. 18-28

L-Dex™ is a trademark of ImpediMed Limited.

" L-Dex™ values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity".

#### **About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. [www.impedimed.com](http://www.impedimed.com).